The US Food and Drug Administration (FDA) has designated Celltrion’s Yuflyma (adalimumab-aaty) as an interchangeable biosimilar to AbbVie’s Humira (adalimumab). The decision allows Yuflyma to be ...

Yuflyma is a high-concentration and citrate-free formulation of Humira biosimilar, approved for multiple inflammatory ...

US FDA designates Celltrion’s Yuflyma as an interchangeable biosimilar to Humira: Incheon, South Korea Wednesday, April 16, 2025, 16:00 Hrs [IST] Celltrion, Inc. announced that ...

The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the treatment of multiple chronic ...

The U.S. Food and Drug Administration has designated Celltrion Inc.’s YUFLYMA (adalimumab-aaty), as an interchangeable biosimilar to Humira.

a significant portion of whom rely on insulin injections, driving the demand for autoinjectors. In 2023, North America accounted for the highest prescription rates for autoinjectors, with more ...

This rise is brought about mainly by the growing demand for self-injection devices, technological innovations in autoinjector systems, and an increase in the prevalence of chronic diseases such as ...

Consumers warned of potential risks of counterfeit injection pens sold as Ozempic Patients are being urged not to use Ozempic (semaglutide) bearing the batch number MPSD916, after the Australian ...

Downlevel Functional Tests (1.0.2, 2019, Release, x64) Downlevel Functional Tests (1.0.2, 2022, Release, x64) Downlevel Functional Tests (1.0.2, Prerelease, Release ...